Aug 21, 2025
PTC Therapeutics to Participate at Upcoming Investor Conferences
Aug 07, 2025
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Jul 28, 2025
PTC Therapeutics Announces FDA Approval of Sephience(TM) (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
May 06, 2025
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
May 01, 2025
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 24, 2025
PTC Therapeutics to Participate at Upcoming Investor Conferences
Apr 17, 2025
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results
Mar 20, 2025
PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies
Feb 27, 2025
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Dec 19, 2024
PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia
Dec 17, 2024
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 14, 2024
FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency
Nov 07, 2024
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Oct 25, 2024
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 18, 2024
CHMP Maintains Negative Opinion on Translarna(TM) Reexamination
Oct 01, 2024
PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients
Sep 12, 2024
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 08, 2024
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Jun 28, 2024
CHMP Issues Negative Opinion on Translarna(TM) Following European Commission Request for Review
Jun 21, 2024
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)